Komori
Business alliance4563AnGes,Inc.Pharmaceuticals

Jointly Developed Product Tie2 Receptor Agonist (AV-001): Completion of Enrollment in a Phase 2 Clinical Trial

Additional patient enrollment has been completed for AV-001, which AnGes and Vasomune are co-developing, in the Phase 2a clinical trial currently being conducted in the United States. The companies will proceed with the collection and analysis of trial data, with the aim of obtaining interim updates and topline results.

Worth reading
50Recurring
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Business alliance
4563AnGes,Inc.
Alliance partnerVasomune Therapeutics, Inc.
Details of the alliance
  1. 1

    Co-development of AV-001

  2. 2

    Advancing the clinical development of AV-001

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionA privately held, clinical-stage biopharmaceutical company engaged in developing next-generation pharmaceuticals that enhance the body's protective functions against endothelial damage and increased vascular permeability.
LocationToronto, Canada, and Raleigh, North Carolina, United States
Impact on Business Performance

The completion of enrollment has no impact on consolidated financial results for the fiscal year ending December 2026.

Agreements reached under this partnership
ItemDetails
Name of alliance partnerVasomune Therapeutics, Inc.
Alliance partner's business activitiesA privately held, clinical-stage biopharmaceutical company engaged in developing next-generation pharmaceuticals that enhance the body's protective functions against endothelial damage and increased vascular permeability.
Alliance partner's locationToronto, Canada, and Raleigh, North Carolina, United States
Type of allianceBusiness alliance
Details of the allianceCo-development of AV-001, Advancing the clinical development of AV-001
Impact on Business PerformanceThe completion of enrollment has no impact on consolidated financial results for the fiscal year ending December 2026.
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because additional enrollment was continued to address patient dropouts after the planned completion of patient enrollment by the end of 2025.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Jointly Developed Product Tie2 Receptor Agonist (AV-001): Completion of Enrollment in a Phase 2 Clinical Trial | AnGes,Inc. (4563) timely disclosure | Komori